Chiesi
Sales and Marketing/ Views & Analysis/ Views and analysis
The benefits of being a family-run pharma company
mike.hammerton@pharmaphorum.com
Chiesi, Rare diseases
0 Comment
Switch data back Chiesi/Protalix long-acting Fabry drug
Phil Taylor
Chiesi, Fabrazyme, Fabry disease, Protalix, rare disease, Replagal, Sanofi Genzyme, Takeda
0 Comment
Moderna broadens R&D scope with Vertex, Chiesi alliances
Phil Taylor
Chiesi, cystic fibrosis, Moderna, partnership, pulmonary arterial hypertension, Vertex Pharma
0 Comment
Market Access/ News/ News/ Top stories
Chiesi’s flagship Fabry drug heads for FDA verdict in early 2021
Phil Taylor
Chiesi, Fabry disease, Protalix, rare disease
0 Comment
Chiesi starts rare diseases division, ahead of potential Fabry disease filing
Richard Staines
Chiesi, Fabry disease, Protalix, R&D, Rare diseases, respiratory, Takeda
0 Comment
FDA rejection scuppers AZ’s hopes of a COPD triple clash with GSK
Phil Taylor
AstraZeneca, Chiesi, COPD, GlaxoSmithKline, respiratory
0 Comment
GlaxoSmithKline/ Market Access/ News/ News/ News/ R&D/ R&D/ UK & Europe
Verona to take COPD hopeful into phase 3
Richard Staines
Chiesi, COPD, GlaxoSmithKline, R&D, respiratory
0 Comment